Cellectar Biosciences, Inc. Earnings Recaps
Q3 2025
Nov 14, 2025
Cellectar Biosciences, Inc. reported a strong third quarter in 2025, bolstered by advances in regulatory strategies for its lead asset, iopofosine I-131, and significant progress in its clinical pipelines.
Key takeaways
- Received confirmation from the EMA for conditional marketing authorization eligibility for iopofosine I-131, positioning the drug for potential EU approval as early as 2027.
- Plans to submit a New Drug Application (NDA) to the FDA under the accelerated approval pathway, following favorable twelve-month follow-up data from the Clover Wham study.
- Successfully raised approximately $12.7 million in recent financing to strengthen the balance sheet and support ongoing trial initiatives.
- Progressed in early-phase studies of next-generation radiopharmaceuticals CLR125 and CLR225, targeting various solid tumors, with notable presentations at major cancer research conferences.
- Enhanced strategic partnerships discussions aimed at expediting commercialization and securing non-dilutive capital for iopofosine I-131.
Q2 2025
Aug 14, 2025
Cellectar Biosciences reported a strong second quarter, showcasing strategic advances in its clinical pipeline and regulatory strategies while securing additional funding to support future initiatives.
Key takeaways
- Submitted a new drug application for iopofosine I-131 for Waldenstrom's Macroglobulinemia under an accelerated approval pathway, emphasizing commitment to expedite treatment for rare diseases.
- Secured €5.8 million in financing, boosting cash reserves to $11 million, sufficient to fund operations through Q2 2026.
- Advanced discussions with potential partners to secure non-dilutive capital and expertise for iopofosine's global commercialization.
- Research and development expenses significantly decreased to $2.4 million due to completed patient enrollment in the CLOVER-WaM study.
- Timeline established for initiating a Phase I trial of CLR 125 in late 2025 or early 2026, expanding the company's radiopharmaceutical offerings.